| Revenue growth | 19% YoY for FY26 to ₹904 crores. |
|---|---|
| Margins | Adjusted EBITDA margin at 13.4% for FY26. |
| Demand visibility | Strong trust with customers; growing relevance in CDMO space. |
| Management confidence | High; citing 13 consecutive quarters of record revenue. |
Growth
FY26 Revenue: ₹904cr (+19%); Q4 Revenue: ₹238cr (+18%). FY26 Adjusted EBITDA: ₹121cr (13.4%); PAT: ₹83cr (9.2%).
Outlook
Plant 6 commercialization by H1 FY27; targeting ₹1,000cr+ revenue capacity; expanding injectables and export vertical growth.
Risks
Regulatory intensity increasing; supply disruptions/API price hikes due to West Asia crisis; loss of codeine-based syrup business.
Earnings Call filed with BSE, NSE: WINDLAS. Summary written with AI assistance from the document.
Windlas Biotech Ltd: key numbers
- Share price
- ₹1,029.00
- Market cap
- ₹2,160 Cr
- Revenue (annual)
- ₹904.1 Cr
- Net profit (annual)
- ₹66.44 Cr
- P/E (TTM)
- 32.5×Sector 47.4×
- Promoter holding
- 63.31%+1.41% QoQ
- FII holding
- 2.04%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Windlas Biotech Ltd
All →Windlas Biotech Earnings Call Transcript: Key Takeaways
Windlas Biotech reported record quarterly revenue driven by 29% growth in CDMO vertical. Management focuses on operational excellence and capacity expansion via Plant 6 commercialization.
Windlas Biotech Results Update
Windlas Biotech reported Q1 FY27 revenue of Rs 248 crore, an 18% YoY growth. The release highlights an adjusted EBITDA of Rs 34 crore and PAT of Rs 25 crore.
Windlas Biotech Investor Presentation: Key Takeaways
Windlas Biotech reported Q1FY27 revenue of ₹248 Cr (18% YoY). Adjusted EBITDA and PAT grew 26% and 37% respectively, excluding ESOP costs, driven by CDMO expansion.
Windlas Biotech Q1 FY27 Results: Net Profit ₹17.7 Cr, Up 0.0% YoY
Windlas Biotech Ltd reported revenue from operations of ₹248.1 Cr (+18.1% YoY) and net profit of ₹17.7 Cr (+0.0% YoY) for Q1 FY27.
- Key figure
- Net profit ₹17.7 Cr · +0.0% YoY
Windlas Biotech Board Meeting Date
Windlas Biotech Limited has scheduled a board meeting on August 10, 2026, to consider and approve its unaudited standalone financial results for the quarter ending June 30, 2026.
Windlas Biotech Annual General Meeting
Windlas Biotech Ltd held its 25th Annual General Meeting on July 23, 2026. Shareholders approved the financial statements and a final dividend of Rs. 6.30 per share.